Ameloblastic carcinoma, secondary type: a case report

Karakida, Kazunari; Aoki, Takayuki; Sakamoto, Haruo; Takahashi, Miho; Akamatsu, Tadashi; Ogura, Go; Sekido, Yasutomo; Ota, Yoshihide

doi:10.1016/j.tripleo.2010.08.018

Cited by 45 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The higher expression of p53 found in ACs as compared to AMs suggest that this protein may play a role in malignant transformation, as has been also suggested by other authors (9-11). However, data regarding p53 expression in ACs varies in different studies; for example, studies performed by Yoon et al , (2); Karakida et al , (12); Matsuzaki et al (10), and Nobusawa et al , (13) described p53 overexpression in almost all tumor cells of the carcinoma component, while it was negative in the benign ameloblastic areas; however, Abiko et al (14) found that both benign and malignant areas of one case of AC were negative for p53 by immunohistochemistry. In our opinion the information obtained in a single case is not enough to compare with our findings, and with those found by the other authors that based their studies in series of cases that have followed a similar sample processing and analysis, with less probabilities of misdiagnosis and technical errors.…”

Section: Discussionmentioning

confidence: 99%

Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas

et al. 2017

View full text Add to dashboard Cite

Background: This study aimed to compare the histological and immunohistochemical characteristics of ameloblastomas (AM) and ameloblastic carcinomas (AC). Material and Methods: Fifteen cases of AM and 9 AC were submitted to hematoxilin and eosin (H&E) and immunohistochemical analysis with the following antibodies: cytokeratins 5,7,8,14 and 19, Ki-67, p53, p63 and the cellular adhesion molecules CD138 (Syndecan-1), E-cadherin and β-catenin. The mean score of the expression of Ki-67 and p53 labelling index (LIs) were compared between the groups using the t test. A value of p<0.05 was considered to be statistically significant. Results: All cases were positive for CKs 5, 14 and 19, but negative for CKs 7 and 8. CKs 5 and 19 were positive mainly in the central regions of the ameloblastic islands, while the expression in AC was variable in intensity and localization. CK14 was also variably expressed in both AM and AC. Ki-67 (P=.001) and p53 (P=.004) immunoexpression was higher in AC. All cases were positive for p63, but values were higher in AC. CD138 was mainly expressed in peripheral cells of AM, with a weak positivity in the central areas, while it was positive in most areas of ACs, except in less differentiated regions, where expression was decreased or lost. E-cadherin and β-catenin were weakly positive in both AM and AC.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Diagnosing AMECA becomes even more challenging when we consider that ameloblastomatous differentiation, transitions between clear and non‐clear cells and monophasic clear‐cell islands have been observed in both AMECA and clear‐cell odontogenic carcinoma (CCOC) . Because of this, Hall's group have supported the admission of CCOC as a clear‐cell subtype of the AMECA.…”

Section: Discussionmentioning

confidence: 99%

Ameloblastic carcinoma: a Brazilian collaborative study of 17 cases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…3,4 Ameloblastic carcinoma which is different entity form malignant ameloblastoma is a rare malignant odontogenic tumour. 5 In fact in 2005, The World Health Organization have reclassified odontogenictumours and defined it as anodontogenic malignancy that combines the histological features of ameloblastoma with cyctologicatypia, even in the absence of metastases. It may develop de no vo (primary type) or by malignant transformation of an ameloblastoma (secondary type) with a distinction between intraosseous and periphery ameloblastoma.…”

Section: Introductionmentioning

confidence: 99%

Ameloblastic carcinoma of the mandible

Purmal

Alam

Pohchi

et al. 2015

Bangladesh J Med Sci

View full text Add to dashboard Cite

Abstract:Ameloblastic carcinoma is a highly malignant tumour and requires aggressive treatment. This case report describes an aggressive ameloblastic carcinoma that infiltrated the mandible. Mandibulectomy with right functional radical neck dissection and left supra omohyoid dissection was followed by primary reconstruction with a single free vascularised fibula flap. The postoperative course was uneventful. The 2 year regular follow up revealed no signs of recurrent tumour or metastasis. Future reporting of this rare condition is encouraged in lieu of limited information in its clinical course and prognosis.

show abstract

Ameloblastic carcinoma, secondary type: a case report

Cited by 45 publications

References 17 publications

Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas

Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas

Ameloblastic carcinoma: a Brazilian collaborative study of 17 cases

Ameloblastic carcinoma of the mandible

Contact Info

Product

Resources

About